Login to Your Account



Advancis Stock Takes Tumble As GSK Ends Augmentin Deal

By Randall Osborne


Wednesday, October 20, 2004
Advancis Pharmaceutical Corp.'s stock was pounded severely, losing more than 60 percent of its value, on news that GlaxoSmithKline plc has decided to break off the deal to use Pulsys technology with Augmentin - a project that had been aimed for Phase III trials next year and could have meant $49 million in development milestones eventually, plus $50 million in sales milestones apart from royalties. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription